Cumberland Pharmaceuticals Inc.
(NASDAQ:CPIX) stock is trading higher on Friday following positive updates from the company's Phase 2 FIGHT DMD trial, which evaluates ifetroban for Duchenne muscular dystrophy (DMD) heart disease.
Cumberland Pharma Stock Jumps On Phase 2 FIGHT DMD Trial Update Cumberland Pharmaceuticals recently presented updated results from its Phase 2 FIGHT DMD trial at the Parent Project Muscular Dystrophy conference, showcasing ifetroban's cardioprotective effects in DMD patients.
The trial demonstrated a significant 5.4% improvement in left ventricular ejection fraction and reductions in cardiac damage markers, reinforcing the drug's potential to address a critical unmet need in treating DMD-related cardiomyopathy.
Read Also: REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval Long-Term Safety Data Reinforces Ifetroban Profile New findings from the Phase 2 FIGHT DMD trial, supported by long-term safety data from the ongoing open-label extension, further characterize the cardioprotective effect exerted by ifetroban in DMD cardiomyopathy.
